Erythrodermic Psoriasis: Current and Future Role of Biologicals
- 10 March 2015
- journal article
- Published by Springer Science and Business Media LLC in BioDrugs
- Vol. 29 (2), 91-101
- https://doi.org/10.1007/s40259-015-0119-4
Abstract
Erythrodermic psoriasis (EP) is a severe form of psoriasis that may be associated with serious and sometimes fatal complications. The treatment of EP is often a challenge, since several factors, including treatment failure or possible complications, may limit favorable outcomes with traditional drugs. Recent evidence suggests that biological drugs, including both anti-tumor necrosis factor alpha agents and ustekinumab, may be useful in improving the management of EP. Unfortunately, since subjects with EP are usually excluded from pivotal trials involving biological agents, this evidence is currently dispersed in small case series and single case reports. In this paper, we briefly analyze conventional therapies for EP, before going on to critically evaluate the existing clinical evidence for the role of current biological drugs, namely infliximab, etanercept, adalimumab, and ustekinumab. Finally, we discuss the potential benefits that newer/developmental biological agents could bring to the management of EP.Keywords
This publication has 53 references indexed in Scilit:
- Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two CasesCase Reports in Dermatology, 2013
- Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010Journal of the American Academy of Dermatology, 2012
- Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapiesThe Journal of Dermatology, 2012
- A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunityBritish Journal of Dermatology, 2006
- Methotrexate and ciclosporin combination for the treatment of severe psoriasisClinical and Experimental Dermatology, 2006
- Dramatic improvement of psoriatic erythroderma after acute hepatitis: analysis of cytokine synthesis capability in peripheral blood T cellsBritish Journal of Dermatology, 2006
- Serum immunoglobulins in psoriatic erythrodermaClinical and Experimental Dermatology, 2005
- Detection of circulating adhesion molecules in erythrodermic skin diseaseJournal of the American Academy of Dermatology, 1995
- Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasisJournal of the American Academy of Dermatology, 1994
- Combination therapy for psoriasis with methotrexate and etretinateJournal of the American Academy of Dermatology, 1986